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Abstract
Purpose The primary objective of this phase I dose-
escalation study was to identify the maximum tolerated
dose (MTD) of sunitinib plus pemetrexed in patients with
advanced cancer.
Methods Using a 3 ? 3 dose-escalation design, patients
received oral sunitinib qd by continuous daily dosing (CDD
schedule; 37.5 or 50 mg) or 2 weeks on/1 week off treat-
ment schedule (Schedule 2/1; 50 mg). Pemetrexed
(300–500 mg/m
2 IV) was administered q3w. At the pro-
posed recommended phase 2 dose (RP2D), additional
patients with non-small cell lung cancer (NSCLC) were
enrolled.
Results Thirty-ﬁve patients were enrolled on the CDD
schedule and seven on Schedule 2/1. MTDs were sunitinib
37.5 mg/day (CDD/RP2D) or 50 mg/day (Schedule 2/1)
with pemetrexed 500 mg/m
2. Dose-limiting toxicities
included grade (G) 5 cerebral hemorrhage, G3 febrile
neutropenia, and G3 anorexia. Common G3/4 drug-related
non-hematologic adverse events (AEs) at the CDD MTD
included fatigue, anorexia, and hand–foot syndrome. G3/4
hematologic AEs included lymphopenia, neutropenia, and
thrombocytopenia. No signiﬁcant drug–drug interactions
were identiﬁed. Five (24%) NSCLC patients had partial
responses.
Conclusions In patients with advanced solid malignan-
cies, the MTD of sunitinib plus 500 mg/m
2 pemetrexed
was 37.5 mg/day (CDD schedule) or 50 mg/day (Schedule
2/1). The CDD schedule MTD was tolerable and demon-
strated promising clinical beneﬁt in NSCLC.
Keywords Antiangiogenic  Pemetrexed  Phase I  Solid
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Introduction
Additive or synergistic preclinical effects are observed
when antiangiogenic agents are combined with chemo-
therapy [1–3]. In clinical trials, the addition of bev-
acizumab, an anti-vascular endothelial growth factor
(VEGF) targeting monoclonal antibody, to chemotherapy,
improved efﬁcacy, compared with chemotherapy alone in
patients with advanced, non-squamous, non-small cell lung
cancer (NSCLC) [4, 5], and colorectal cancer [6]. Simi-
larly, the combination of the chemotherapeutic agent
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itor (TKI), sunitinib, could potentially offer a therapeutic
advantage over pemetrexed alone.
Pemetrexed (ALIMTA
), an inhibitor of multiple folate
pathway enzymes, has demonstrated clinical activity in a
broad range of solid tumors, including breast, colorectal,
bladder, cervical, gastric, head and neck, and pancreatic
cancers [7]. Pemetrexed in combination with cisplatin is
approved as standard ﬁrst-line treatment for mesothelioma
and non-squamous, advanced NSCLC [8–10]. Single-agent
pemetrexed is approved as second-line therapy for patients
with non-squamous, advanced NSCLC, due to its compa-
rable efﬁcacy with docetaxel and favorable safety proﬁle
[11]. Pemetrexed is also approved as maintenance therapy,
due to its demonstrated improvement in progression-free
survival (PFS) versus best supportive care alone [12, 13].
However, overall response rates (ORRs) in the second-line
NSCLC setting remain low (\10%) and treatment combi-
nations with improved efﬁcacy are needed [11–13].
Sunitinib (SUTENT
) is an oral antiangiogenic
multitargeted TKI with nanomolar range potency inhib-
iting VEGF receptors (VEGFRs 1–3), platelet-derived
growth factor receptors (PDGFRs a and b), and other
receptors [14]. It is effective in the treatment for renal
cell carcinoma (RCC) and imatinib-resistant or -intolerant
gastrointestinal stromal tumors (GISTs) when adminis-
tered once daily at 50 mg on a schedule of 4 weeks on
treatment followed by 2 weeks off treatment (Schedule
4/2) [15–20]. Antitumor activity with sunitinib has also
been demonstrated in patients with other solid malig-
nancies, including NSCLC, pancreatic neuroendocrine
tumors, sarcoma, thyroid cancer, and melanoma [21–23].
While the optimal dosing schedule for sunitinib has not
been determined or directly compared in the clinical trial
setting, both intermittent and continuous daily dosing
(CDD) schedules have demonstrated similar efﬁcacy and
tolerability in patients with RCC, GIST, and NSCLC [22,
24–29].
As pemetrexed is active in a broad spectrum of tumors,
combining pemetrexed with an antiangiogenic agent such
as sunitinib may improve antitumor activity. Preclinical
additive activity or synergy was demonstrated in NSCLC:
sunitinib decreased tumor growth in NSCLC NCI-H460
xenograft models and pemetrexed enhanced its antitumor
activity [2]. Based on preclinical synergy, and the single-
agent clinical activity of both agents in NSCLC, we
investigated the feasibility, tolerability, and early antitumor
activity of the combination of pemetrexed and sunitinib in
patients with advanced solid malignancies. This treatment
combination was subsequently explored at the recom-
mended phase 2 dose (RP2D) and schedule in an expanded
cohort of patients with advanced NSCLC.
Patients and methods
Study population
Male or female patients, 18 years or older, with Eastern
Cooperative Oncology Group (ECOG) performance status
of 0 or 1 were considered for study entry into the original
cohort. Patients were eligible if they had a diagnosis of a
solid malignancy that was histologically or cytopathologi-
cally conﬁrmed and refractory to standard therapy, or for
which no standard therapy existed. Eligibility criteria
included adequate organ function (including bone marrow,
kidney, and liver), and a life expectancy of C12 weeks. In
the NSCLC expansion cohort, previously treated and/or
platinum refractory/intolerant patients with recurrent or
advanced NSCLC of all histological subtypes were eligible
for enrollment.
Patients were excluded if they had uncontrolled or
symptomatic brain metastases, gross hemoptysis (C5m L
per episode or C10 mL per day) within 4 weeks of study
start, uncontrolled hypertension ([150/100 mmHg) despite
standard antihypertensive agents, or cardiac disease, cere-
brovascular accident or pulmonary embolism within
12 months of starting on study. Other exclusion criteria
included National Cancer Institute (NCI) Common Ter-
minology Criteria for Adverse Events (CTCAE version
3.0) grade 3 hemorrhage within 4 weeks of treatment,
ongoing cardiac dysrhythmias of grade C2, atrial ﬁbrilla-
tion of any grade, prolongation of the QTc interval
([450 ms for men or [470 ms for women), or prior
treatment with pemetrexed or sunitinib.
Study design and treatment
This open-label, multicenter, phase I trial (NCT00528619)
conducted in the US and Canada investigated escalating
doses of sunitinib plus pemetrexed in combination with
serial patient cohorts. The primary end point was the
determination of the toxicity proﬁle to establish the MTDs
of sunitinib administered in combination with pemetrexed
in patients with advanced solid malignancies. Secondary
end points included safety, pharmacokinetic (PK) proﬁle,
and preliminary antitumor activity of this combination.
Sunitinibwasadministeredorallyoncedailyoneither the
CDD schedule or 2 weeks on treatment followed by 1 week
off treatment schedule (Schedule 2/1). Pemetrexed was
administered once every 3 weeks (q3w). Planned dose
cohorts followed a standard dose escalation 3 ? 3 design of
sunitinib (37.5 mg to 50 mg) and pemetrexed (300–500
mg/m
2 IV), beginning with the CDD schedule. Each
treatmentcyclelasted3 weeks,andpatientscouldreceiveup
to eight cycles of combination treatment. When discontin-
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toxicity during the dose-limiting toxicity (DLT) observation
timeframe, patients were replaced. Patients who continued
to receive clinical beneﬁt were eligible to enter a continua-
tion protocol with the combination or with sunitinib alone.
At the discretion of the investigator, patients with progres-
sivediseasewhowerestillbeneﬁtingfromtreatment(e.g.,in
the presence of isolated central nervous system progression)
could also receive sunitinib or the treatment combination
within the same continuation protocol. The MTD was
deﬁnedasthehighestdosecohortwhere0/3orB1/6patients
experienced a DLT, with the next highest dose having at
least 2/3or 2/6 patients who experienced a DLT. DLTs were
deﬁnedastheoccurrenceduringcycle1ofgrade3or4drug-
related toxicities, including neutropenia (grade 3 with
infection; grade 4 C 7 days or febrile[24 h), thrombocy-
topenia (grade C 3 with bleeding or grade 4 C 7 days), and
any grade 3/4 non-hematologic toxicity C7 days or that
resulted in a delay in administration of cycle 2 as scheduled.
IftheMTDontheCDDschedulewasestablishedatsunitinib
50 mg/day ? pemetrexed500 mg/m
2,theMTDonSchedule
2/1 was to be the same dose level without being formally
tested.ProvidedthattheCDDscheduleMTDwasestablished
at sunitinib 37.5 mg/day ?
pemetrexed 500 mg/m
2 or lower, the starting dose for Sche-
dule 2/1 was to be the lowest non-tolerated dose on the CDD
schedule. Depending on the doses of sunitinib determined to
be tolerable on Schedule 2/1 and the CDD schedule, one
cohortwouldbenominatedforfurtherexplorationattheMTD
to establish a proposed RP2D and schedule and expanded to
enroll an additional 15 patients with locally advanced/meta-
static NSCLC (the NSCLC expansion cohort).
Intra-patientdosereduction(relativetothelowestdoseof
the current cycle and at the discretion of the investigator)
was permitted ifa patient experienced a grade 3 or 4toxicity
considered attributable to either study drug, provided that
criteriaforpatientwithdrawalfromstudytreatmentwerenot
met. Guidelines suggested reducing pemetrexed by an
incrementof100 mg/m
2andreducingsunitinibdailydosing
by12.5 mg.Ifgrade3or4toxicitiesrecurred,patientscould
undergo further dose reduction in subsequent cycles up to a
maximum of 2 dose reductions in any drug; the minimum
dose for pemetrexed was 200 mg/m
2 and for sunitinib was
25 mg daily. Assigned doses during the PK portion of the
study(cycle1 day1throughcycle2 day2)weremaintained
when possible to allow for valid comparisons.
The investigator could delay sunitinib dosing for
patients experiencing treatment-related toxicity, but it was
recommended that patients requiring dose delay longer
than 4 weeks in duration on either schedule were with-
drawn. Pemetrexed was withheld if creatinine clearance
was less than 45 mL/min and the decision for future dosing
was then made by the investigator.
All patients provided written, informed consent. The
study was approved by the institutional review board of
each participating center and carried out in accordance with
the International Conference on Harmonization Good
Clinical Practice guidelines and applicable local laws and
regulatory requirements.
Study assessments
Safety was evaluated throughout the study by the assess-
ment of adverse events (AEs; NCI CTCAE version 3.0),
laboratory abnormalities, physical examinations, perfor-
mance status, vital signs, and electrocardiogram (ECG)
proﬁles. AEs considered by the investigator to be related to
either study drug were evaluated to determine the safety of
this combination. In patients with measurable disease,
objective response was determined according to Response
Evaluation Criteria in Solid Tumors (RECIST v.1.0) [30].
Pharmacokinetic assessments
Blood samples for pharmacokinetic (PK) assessment were
collected in K2EDTA tubes and sent to Bioanalytical
Systems Inc (West Lafayette, IN, USA) for analysis. The
plasma PK samples were analyzed using Pﬁzer-proprietary
validated, sensitive, and speciﬁc high-performance liquid
chromatographic tandem mass spectrometric (HPLC–MS/
MS) methods, in compliance with Pﬁzer’s standard oper-
ating procedures.
The analytical method used for the determination of
sunitinib and its metabolite showed precision of B6.1%
(sunitinib) or B8.9% (metabolite), expressed as the
between-day coefﬁcients of variation (%CV) of the mean
estimated concentrations of the quality control (QC) sam-
ples and accuracy ranging from -2.0 to 0.0% (sunitinib) or
-5.0 to 1.4% (metabolite) expressed as the percent relative
error (% RE) of the QC samples. The lower limit of
quantitation (LLOQ) of the assay was 0.100 ng/mL for
both sunitinib and its metabolite, and the upper limit of
quantitation (ULOQ) was 60.0 ng/mL for sunitinib and
20.0 ng/mL for the metabolite.
The analytical method used for the determination of
pemetrexed showed precision of B13.3%, expressed as the
between-day %CV of the mean estimated concentrations of
the QC samples and accuracy ranging from 0.3 to 2.2%
expressed as the % RE of the QC samples. The LLOQ of
the pemetrexed assay was 0.100 lg/mL and the ULOQ was
100 lg/mL.
Full PK proﬁles were obtained from patients on the
CDD schedule for sunitinib, its active metabolite SU12662,
sunitinib ? SU12662, and pemetrexed. Pemetrexed PK
samples were collected on cycle 1 day 1 (i.e., in the
absence of sunitinib) and cycle 2 day 1; predose, and
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Sunitinib PK samples were collected on cycle 1 day 15
(i.e., steady state levels of sunitinib in the absence of
pemetrexed) and on cycle 2 day 1 predosing with
pemetrexed or sunitinib, and then 1, 2, 4, 6, 8, 10, and 24 h
post-sunitinib dosing. Only patients that received at least
10 consecutive doses of sunitinib prior to sample collection
on cycle 1 day 15 and cycle 2 day 1 were included in the
summary to ensure that steady state had been achieved. PK
analyses were performed on both the original dose-esca-
lation cohorts and on the expanded NSCLC cohort. On
Schedule 2/1, samples were collected only on day 1 of
cycle 2.
Statistical methods
Due to the exploratory nature of this study, no conﬁrmatory
inferential statistical analyses were planned. Descriptive
statistics were used to summarize all patient characteristics,
treatment administration/compliance, safety, PK parame-
ters, and antitumor activity. Standard plasma PK parame-
ters were estimated using non-compartmental methods.
Results
Patient characteristics
Twenty patients were enrolled on the CDD schedule, and
seven patients were enrolled on the Schedule 2/1 dose-
escalation cohorts. The patients were men and women with
various types of malignancies and good performance status
(ECOG 0 or 1), as detailed in Table 1. The Schedule 2/1
cohort included one patient who replaced a patient taken
off study for disease progression. Two additional patients
were included on the CDD schedule (one in the sunitinib
37.5 mg ? pemetrexed 400 mg/m
2 cohort and one in the
sunitinib 37.5 mg ? pemetrexed 500 mg/m
2 cohort, due to
simultaneous enrollment of patients for the last slot in the
respective cohorts (Table 1). An additional 15 patients with
NSCLC were subsequently enrolled into the NSCLC
expansion cohort on the CDD schedule (see below). This is
a disease setting where single-agent sunitinib activity was
previously observed [29]. In total, these 42 patients
received 222 cycles of sunitinib therapy and 211 cycles of
pemetrexed therapy (Table 2).
Safety
The MTD on the CDD schedule was determined to be
sunitinib 37.5 mg/day with pemetrexed 500 mg/m
2 q3w.
On Schedule 2/1, at the next highest dose level (sunitinib
50 mg with pemetrexed 500 mg/m
2; n = 7), only one DLT
was observed. All DLTs are described in Table 3.A s
37.5 mg was perceived to be a potentially efﬁcacious dose
and because prolonged target coverage was theoretically
preferred over intermittent target coverage, the CDD MTD
was taken forward as the proposed RP2D into the NSCLC
expansion cohort.
In total, 12 (55%) patients treated on the CDD schedule
MTD had at least one sunitinib dose delay, and the same
number of patients had a pemetrexed dose delay. Three
(14%) patients had dose delays of both sunitinib and
pemetrexed between 3 and 4 weeks, 12 (55%) patients in
this cohort had a sunitinib dose reduction to 25 mg, and 6
(27%) had a pemetrexed dose reduction to 400 mg/m
2.
Three patients discontinued sunitinib at the MTD due to
AEs (abdominal pain, seizure, and thrombocytopenia); only
the thrombocytopenia was considered sunitinib-related. The
median number of cycles of sunitinib and pemetrexed
received was 4 (range: 2–13) in the original CDD schedule
MTD cohort (n = 7) and 5 (range: 1–8) in the NSCLC
expansion cohort (n = 15). Across all patients treated at the
CDD schedule MTD, 11 (50%) patients started at least 5
cycles of sunitinib. Sunitinib dose reductions occurred in 23
(56%) cycles on the original CDD schedule MTD cohort
and 22 (28%) cycles on the NSCLC expansion cohort; 7
(47%) patients in the expansion cohort had at least one
sunitinib dose reduction to 25 mg. Pemetrexed dose
reduction occurred in 13 (32%) cycles on the original CDD
schedule MTD and 6 (8%) cycles in the NSCLC expansion
cohort; 3 (20%) patients in the expansion cohort had at least
one pemetrexed dose reduction to 400 mg/m
2. The median
relative dose intensity (% actual/intended dose intensity) in
the NSCLC expansion cohort across all cycles was 73% for
sunitinib and 94% for pemetrexed. By cycle 5, 8/15 patients
in the NSCLC expansion cohort remained on study and the
median dose intensity was 76% (range: 50–100%) for
sunitinib and 100% (75–100%) for pemetrexed. By cycle 8,
6/15 of these patients remained on study and the median
dose intensity was 81% (range, 52–100%) for sunitinib and
88% (65–100%) for pemetrexed.
Treatment-related AEs at the MTDs on both schedules
and on the NSCLC expansion cohort are shown in Table 4;
these events were predominantly mild to moderate in
severity. The most common non-hematologic AEs related
to either drug, observed in patients treated on the CDD
schedule MTD, were fatigue/asthenia (n = 16; 73%),
nausea (n = 14; 64%), and anorexia (n = 13; 59%). In
patients on the NSCLC expansion cohort, fatigue/asthenia
(n = 11, 73%), nausea (n = 10, 67%), and diarrhea and
dysgeusia (both n = 9, 60%) were most common. Serious
AEs considered related to sunitinib treatment at the MTD
included: febrile neutropenia (DLT), pancreatitis, pain,
gastroenteritis, and muscular weakness (one event of each
in separate patients). Hematologic laboratory abnormalities
712 Cancer Chemother Pharmacol (2012) 69:709–722
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123on the CDD schedule at the MTD included grade 3/4
lymphopenia, n = 7; grade 3 neutropenia, n = 5; and
grade 3/4 thrombocytopenia, n = 4. Grade 2/3 anemia
requiring blood transfusion occurred in nine patients.
The only DLT on Schedule 2/1 was febrile neutropenia
(n = 1) at the highest dose level (sunitinib
50 mg ? pemetrexed 500 mg/m
2, the Schedule 2/1
MTD). The median number of cycles of sunitinib and
pemetrexed received per patient was 4 (range: 1–8) and
dose reductions occurred in 6 (22%) and 3 (11%) cycles
for sunitinib and pemetrexed, respectively (Table 2). Two
patients on Schedule 2/1 had at least one sunitinib dose
delay of 1–2 weeks, and two patients had a sunitinib dose
reduction to 37.5 mg. Most treatment-related non-hema-
tologic AEs were grade 1 or 2, with fatigue being the most
common (n = 6). Serious AEs considered related to sun-
itinib treatment included febrile neutropenia (DLT), tumor
perforation, and pyrexia (all n = 1). Hematologic labora-
tory abnormalities included grade 3/4 neutropenia (n = 2),
grade 3 lymphopenia (n = 3), grade 3 thrombocytopenia
(n = 1), and grade 2/3 anemia requiring blood transfusion
(n = 2).
Across all cohorts, there were 5 deaths (1 at each dose
level of the CDD schedule and 1 on Schedule 2/1). Most
deaths were not considered related to the study drug;
however, in a patient with metastatic bladder cancer on the
CDDscheduletreatedwithsunitinib50 mgandpemetrexed
500 mg/m
2 (above the MTD) who died of cerebral hem-
orrhage (day 14 cycle 1), a relationship to sunitinib expo-
sure could not be ruled out. Prior to study entry, the patient
had risk factors for a cerebral vascular accident, including a
long-standing history of hypercholesterolemia, diabetes,
and hypertension. One patient died at the MTD on the CDD
schedule secondary to respiratory distress during the third
treatment cycle, and one patient died on the Schedule 2/1
MTD from hepatic failure during cycle 5 (both caused by
diseaseprogression).Diseaseprogressionwasalsorecorded
as the cause of death for one patient on the CDD schedule
treated with sunitinib 37.5 mg and pemetrexed 400 mg/m
2
during cycle 4. Cardiac arrest during cycle 4 was the cause
of death of one patient on the CDD schedule (sunitinib
37.5 mg and pemetrexed 300 mg/m
2); this was considered
to result from pericardial effusion due to mesothelioma and
was not considered related to the study drug.
Pharmacokinetics
PK data revealed no clinically signiﬁcant drug–drug inter-
actions with co-administration of sunitinib (sunitinib, its
active metabolite SU12662, and sunitinib ? SU12662) and
pemetrexed (all dose levels). On the CDD schedule at the
MTD, the geometric mean ratios (sunitinib ? pemetrexed
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123maximum (Cmax) and total (AUC24) plasma exposure were
1.00 and 0.98 for sunitinib, respectively. Similarly, the
geometric mean ratios were 1.07 and 1.04 for suniti-
nib ? SU12662, respectively. These data suggest that the
PK of sunitinib when co-administered with pemetrexed
were equivalent to when it was administered alone. On
Schedule 2/1, sunitinib, SU12662, and sunitinib ?
SU12662 PK parameters for day 1 of cycle 2 were not
compared to those for day 15 of cycle 1, as the latter data
corresponded to steady state levels; conversely, the data
collected on day 1 of cycle 2 corresponded to the ﬁrst day of
dosingaftertheweekofftreatment.Duetothesmallnumber
of PK evaluable patients on Schedule 2/1 (n = 4), the PK
data on day 1 of cycle 2 when sunitinib was co-administered
with pemetrexed could not be compared to historical control
data of sunitinib alone. On the CDD schedule, at the MTD,
the geometric mean ratios (sunitinib ? pemetrexed relative
to pemetrexed alone) of pemetrexed Cmax and AUC? were
1.07 and 0.94, respectively. On Schedule 2/1, the respective
geometric mean ratios (sunitinib ? pemetrexed relative to
pemetrexed alone) of pemetrexed Cmax and AUC? were
1.19 and 0.93. Therefore, based on these data, co-adminis-
tration of sunitinib did not appear to affect the PK of
pemetrexed.
Furthermore, a comparison of the dose-corrected PK
parameters at the MTD on the CDD schedule for sunitinib,
SU12662, sunitinib ? SU12662, and pemetrexed sug-
gested similar PK proﬁles in patients with NSCLC and
patients with other types of solid tumors. Dose-corrected
PK parameters at the MTD were calculated using the PK
parameters derived from the concentration–time proﬁles of
all dose levels administered with paired PK observations.
PK data at the MTD on both schedules are shown in
Table 5 and Fig. 1.
Table 2 Dose levels and
treatment durations for sunitinib
and pemetrexed
Continuation data are not
included
CDD continuous daily dosing,
MTD maximum tolerated dose,
N/A not applicable
Pemetrexed
dose (mg/m
2)
Sunitinib
dose (mg)
Number
of patients
Cycles of
sunitinib
therapy started
Cycles of
pemetrexed
therapy
started
CDD schedule (n = 35)
Dose level -1 200 25 N/A N/A N/A
Dose level 1 (starting dose) 300 37.5 3 19 19
Dose level 2 400 37.5 4 28 23
Dose level 3 (MTD) 500 37.5 7 41 35
Expansion cohort 500 37.5 15 78 78
Dose level 4 500 50 6 29 29
Total 35 195 184
Schedule 2/1 (n = 7)
Dose level D 500 50 7 27 27
Total (schedule 2/1 ? CDD
schedule)
42 222 211
Table 3 Dose-limiting toxicities
Sunitinib dose (mg) Pemetrexed
dose (mg/m
2)
n DLT details
b
CDD schedule (n = 35)
37.5
a 500
a 22 Grade 3 febrile neutropenia (n = 1)
50 500 6 Grade 5 cerebral hemorrhage (n = 1) Grade 3 anorexia (n = 1)
Schedule 2/1 (n = 7)
50
a 500
a 7 Grade 3 febrile neutropenia (n = 1)
CDD continuous daily dosing, DLT dose-limiting toxicity, MTD maximum tolerated dose
a Maximum tolerated dose
b If a DLT was experienced by only one of the three patients at any dose level, the cohort was expanded to six patients. If none of the additional
three patients experienced a DLT, the dose was escalated to the next level. If DLTs occurred in two or more patients at any dose level, the dose
level was deemed to have exceeded the MTD and the prior, lower dose level was further expanded (if only three patients were previously treated
at that dose level). The MTD was deﬁned as the dose level at which no more than one patient in a cohort of six patients experienced a DLT during
the ﬁrst treatment cycle of each schedule
Cancer Chemother Pharmacol (2012) 69:709–722 715
123Antitumor activity
Of 32 evaluable patients treated with sunitinib ? pemetr-
exed on the CDD schedule, the best conﬁrmed objective
response was partial response (PR) in six (19%) patients
and stable disease (SD) C8 weeks in 11 (34%) patients, for
an overall ORR of 19%. The two patients with PRs on the
original CDD schedule cohorts had primary diagnoses of
bile duct cancer (treated in the sunitinib 37.5 mg ?
pemetrexed 300 mg/m
2 cohort) and NSCLC classiﬁed as
adenocarcinoma (sunitinib 50 mg ? pemetrexed 500 mg/
m
2). Four patients on the CDD NSCLC expansion cohort,
with histologies of adenocarcinoma (n = 2) and large cell
carcinoma (n = 2), also had PRs. All had received prior
doublet chemotherapy, and two responses were observed in
patients with adenocarcinoma who had received prior
Table 4 Treatment-related (pemetrexed or sunitinib), non-hematologic adverse events of special interest or experienced by C15% patients
treated at the maximum tolerated doses
Adverse event, n (%) Sunitinib 37.5 mg CDD
schedule ? pemetrexed
500 mg/m
2 (n = 7)
Sunitinib 37.5 mg CDD
schedule ? pemetrexed 500 mg/m
2
(NSCLC expansion cohort, n = 15)
Sunitinib 50 mg Schedule
2/1 ? pemetrexed 500 mg/m
2
(n = 7)
Grade 3/4 n (%) Total n (%) Grade 3/4
a n (%) Total n (%) Grade 3/4 n (%) Total n (%)
Non-hematologic
Fatigue/asthenia 2 (29) 5 (71) 1 (7) 11 (73) 1 (14) 6 (86)
Nausea 0 4 (57) 0 10 (67) 1 (14) 4 (57)
Anorexia 2 (29) 6 (86) 0 7 (47) 1 (14) 3 (43)
Diarrhea 1 (14) 3 (43) 0 9 (60) 0 3 (43)
Dysgeusia 0 4 (57) 0 9 (60) 0 2 (29)
Increased lacrimation 0 2 (29) 0 8 (53) 0 3 (43)
Dyspepsia 0 1 (14) 0 7 (47) 0 2 (29)
Vomiting 0 3 (43) 0 4 (26) 0 2 (29)
Constipation 0 4 (57) 0 2 (13) 0 3 (43)
Epistaxis 0 0 0 6 (40) 0 2 (29)
Yellow skin 0 1 (14) 0 5 (33) 0 2 (29)
Face edema 0 0 0 3 (20) 0 2 (29)
Peripheral edema 0 2 (29) 0 4 (26) 0 0
Periorbital edema 0 2 (29) 0 4 (26) 1 (14) 1 (14)
Pyrexia 0 3 (43) 0 0 0 2 (29)
Headache 0 1 (14) 0 2 (13) 0 2 (29)
Rhinorrhea 0 0 0 5 (33) 0 0
Hand–foot syndrome 0 1 (14) 2 (13) 3 (20) 0 1 (14)
Hypertension 0 1 (14) 0 3 (20) 0 1 (14)
Ocular hyperemia 0 1 (14) 0 3 (20) 0 1 (14)
Stomatitis 0 2 (29) 0 3 (20) 0 0
Rash 0 0 0 3 (20) 0 2 (29)
Dry mouth 0 2 (29) 0 2 (13) 0 0
Skin discoloration 0 0 0 2 (13) 0 2 (29)
Contusion 0 0 0 4 (26) 0 0
Hair color changes 0 0 0 4 (26) 0 0
Dry skin 0 3 (43) 0 0 0 0
Blister(s) 0 2 (29) 0 1 (7) 0 0
Erythema 0 0 0 1 (7) 0 2 (29)
Nasal dryness 0 0 0 3 (20) 0 0
Ascites 0 2 (29) 0 0 0 0
Chills 0 0 0 0 0 2 (29)
CDD continuous daily dosing, MTD maximum tolerated dose, NSCLC non-small cell lung cancer
a Most common grade 2 treatment-related AEs on the NSCLC expansion cohort included fatigue n = 8 (53%), increased lacrimation and
decreased appetite, both n = 4 (27%)
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123bevacizumab and erlotinib, respectively. Of seven evalu-
able patients treated with sunitinib on Schedule 2/1, the
best conﬁrmed objective response was SD C8 weeks in
two (28.6%) patients (maintained for 12–20 weeks) with
primary diagnoses of NSCLC (adenocarcinoma) and anal
cancer (squamous cell carcinoma).
Of the 21 patients with NSCLC treated in the dose-
escalation and CDD expansion cohorts, ﬁve (24%) had
PRs, seven (33%) had SD, and ﬁve (24%) had
progressive disease (Table 6). The ORR among the 18
patients with NSCLC treated at the MTD on the CDD
schedule was 24%. Sunitinib (25–50 mg/day) was
administered to eight patients with NSCLC who were
enrolled on a continuation study upon completion of 8
cycles of sunitinib/pemetrexed or at the discretion of the
investigator. Best overall responses in these continuation
patients (taking into account time spent on both the
original and continuation protocols) included four
Fig. 1 Plasma concentration–
time proﬁles of a sunitinib,
b SU12662,
c sunitinib ? SU12662, and
d pemetrexed on the CDD
schedule (patients with paired
observations). C cycle, D day
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123patients who maintained PRs for a median of
11.5 months (range: 8.1–14.6 months), with a median
PFS of 14.6 months (95% conﬁdence interval [CI] 2.6–
NA, n = 4). Additionally, SD for [12 months was
achieved in two patients (13.6 and 12.8 months).
Discussion
The primary objective of this phase I dose-escalation study
was to assess the MTD, safety, and tolerability of sunitinib,
administered on the CDD schedule or Schedule 2/1, in
combination with pemetrexed in patients with advanced
solid malignancies refractory to standard therapy or for
which standard therapy was not available. In anticipation
that this combination could potentially be used in patients
with advanced NSCLC or mesothelioma, the MTD cohort
was expanded to further deﬁne the safety and antitumor
activity for the RP2D.
The MTD on the CDD schedule was sunitinib 37.5
mg/day ? pemetrexed 500 mg/m
2 q3w. On Schedule 2/1,
the MTD was sunitinib 50 mg/day ? pemetrexed 500
mg/m
2 q3w, and this dose level was the maximum tested
on this schedule. The overall safety proﬁle at or below the
MTD was generally tolerable and clinically manageable on
both sunitinib treatment schedules, with most toxicities
being mild or moderate (grade 1 or 2), and similar to those
reported with either single-agent sunitinib or pemetrexed in
advanced NSCLC [11, 22]. The individual immediate
toxicity proﬁles of pemetrexed or sunitinib were not sub-
stantially adversely affected in combination. Pemetrexed
could be administered at clinically efﬁcacious doses for a
median of 4.5 cycles in combination with sunitinib in the
expanded NSCLC continuous daily dosing cohort. It is
unclear whether there is a difference in the long-term tol-
erability of the CDD schedule and Schedule 2/1, as only
two patients were administered sunitinib beyond cycle 5 at
the sunitinib starting (MTD) dose on Schedule 2/1. Despite
Table 6 Responses in patients with NSCLC (all cohorts; n = 21)
Patient NSCLC histology Cohort Best response Rolled over
onto continuation
protocol?
Total time on study (months;
up to June 2010 for
continuation patients
b)
1 Adenocarcinoma Dose Level 4 Partial response Y 19.8
2 Large cell carcinoma CDD expansion Partial response N 3.2
3 Large cell carcinoma
a CDD expansion Partial response Y 18.7
4 Adenocarcinoma CDD expansion Partial response Y 14.7
5 Adenocarcinoma CDD expansion Partial response Y 13.6
6 Adenocarcinoma CDD MTD Stable disease Y 13.4
7 Adenocarcinoma Schedule 2/1 Stable disease N 4.0
8 Unknown CDD expansion Stable disease N 4.6
9 Bronchioloalveolar CDD expansion Stable disease Y 12.6
10 Adenocarcinoma CDD expansion Stable disease N 3.8
11 Squamous cell CDD expansion Stable disease N 5.8
12 Adenocarcinoma CDD expansion Stable disease N 5.5
13 Adenocarcinoma CDD MTD Progressive disease N 2.8
14 Squamous cell Schedule 2/1 Progressive disease N 1.1
15 Other (moderately differentiated) CDD expansion Progressive disease
c Y 15.0
16 Adenocarcinoma CDD expansion Progressive disease
c Y 10.0
17 Squamous cell CDD expansion Progressive disease N 0.7
18 Adenocarcinoma CDD expansion Unknown N 1.8
19 Adenocarcinoma CDD MTD Unknown N 2.5
20 Adenocarcinoma CDD expansion Not evaluable N 0.9
21 Adenocarcinoma CDD expansion Not evaluable N 3.2
CDD continuous daily dosing, MTD maximum tolerated dose, N/A not applicable, NSCLC non-small cell lung cancer
a Histology conﬁrmed by site investigator
b All rollover patients were still alive at time of data collection
c Two patients had intracranial progressive disease (subsequently treated with radiation therapy) but were allowed to continue therapy as they
were experiencing clinical beneﬁt in the opinion of the investigator
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123the initial tolerability of these doses in the ﬁrst cycles of
treatment (from which the DLTs and MTD were deﬁned),
many patients ultimately required dose reductions or dose
delays. However, the chosen RP2D and schedule offered
the potential for the highest possible systemic exposures
over several cycles before individual tailoring of the regi-
men was required. In the expanded cohort at the MTD, the
dose intensity of pemetrexed was well maintained at
500 mg/m
2 without the need for any signiﬁcant dose
reductions; however, continuous daily dosing of sunitinib
at 37.5 mg did require subsequent dose reductions to
25 mg after several cycles in half the patients, predomi-
nantly due to fatigue and anemia, suggestive of additive
and cumulative toxicity. Nevertheless, despite the delays
and dose reductions, the chosen RP2D offered long-term,
sustained tolerability based on the stabilization of the
dosing intensity after cycle 5 and potential efﬁcacy in the
patients treated. The starting dose of sunitinib at 37.5 mg
has demonstrated clinically relevant antitumor activity and
has been shown to achieve the target plasma concentrations
(50–100 ng/mL) required to inhibit VEGFR and PDGFR
phosphorylation, with the associated sustained inhibition of
angiogenic targets [14, 15, 31]. It is possible that even
lower doses of sunitinib may be sufﬁcient to maintain
clinical efﬁcacy in some patients, since there were two
patients with NSCLC on the MTD expansion cohort that
maintained a tumor status of PR for an extended period (up
to cycle 8) following a sunitinib dose reduction to 25 mg.
Antitumor activity was promising in this phase I clinical
trial. The ORR among the 18 patients with NSCLC treated
at the MTD on the CDD schedule was 23.5%, which is
higher than the response rate reported for single-agent
pemetrexed (9% ORR [12]) or sunitinib (ORR 11.1% on
Schedule 4/2 and 2.1% on schedule CDD [22, 29]) in
similar NSCLC patient populations. After entering the
continuation study, four patients with NSCLC (with his-
tologies of adenocarcinoma, n = 3 and large cell carci-
noma, n = 1) achieved extended PRs (durations of
8.1–14.6 months) and two other patients maintained SD for
[12 months (13.6 and 12.8 months, respectively). Median
PFS in NSCLC patients in the continuation cohort was
14.6 months (95% CI 2.6–NA, n = 4).
Although antiangiogenic agents were demonstrated to
be clinically active, their optimal scheduling and dosing
alone and in combination with chemotherapy were not
known at the time of study conduct. Preclinical studies
suggest that angiogenesis inhibitors are most effective
when administered at a dose and schedule that maintains a
constant therapeutic concentration of the inhibitor in the
circulation, whereas cytotoxic drugs should be adminis-
tered at their MTDs followed by off-therapy intervals to
recover from toxicity [32, 33]. Both the low dose contin-
uous (37.5 mg CDD) and higher dose discontinuous dosing
schedules (50 mg Schedule 4/2) of sunitinib alone had
demonstrated efﬁcacy and tolerability in RCC and GIST
[24–29]. Although both schedules of sunitinib at the MTD
were well tolerated in this study, it was felt that a lower
continuous daily dose of sunitinib with pemetrexed might
be more tolerable and potentially have more clinical
activity than higher intermittent dosing. Moreover, our PK
analyses revealed no evidence of drug–drug interactions
with co-administration of sunitinib and pemetrexed or any
evidence of drug accumulation after sunitinib CDD.
Additionally, the phase II clinical trial of sunitinib alone at
37.5 mg on a CDD schedule in advanced refractory
NSCLC demonstrated tolerability and efﬁcacy without
evidence of drug accumulation [29]. All these factors led to
the decision by the clinical investigators to establish the
RP2D and to expand the sunitinib CDD schedule in
NSCLC patients. The CDD approach is supported by a
recent phase III trial demonstrating efﬁcacy and tolerability
of sunitinib in pancreatic neuroendocrine tumors [34],
whereas new data in RCC patients demonstrate similar
efﬁcacy of the CDD and discontinuous dosing schedules,
but a lower toxicity and an improved tolerability proﬁle
with discontinuous dosing [35]. Clearly, there are still
unanswered questions regarding sunitinib scheduling, and a
difference between dosing schedules in toxicity might not
be observed in every clinical setting [29].
At the time of study conduct, the optimal sequencing of
antiangiogenic agents with chemotherapy had not been
previously explored. Although antiangiogenic agents dem-
onstrate additive or synergistic antitumor effects in com-
bination with cytotoxic agents by transiently normalizing
tumor vasculature, enhancing permeability, reducing
interstitial pressure, facilitating chemotherapy diffusion,
and reducing intratumoral hypoxia to enhance cytotoxic
drug delivery to the tumor mass; concurrent therapy may
also synergistically suppress bone marrow cellular pro-
duction and increase toxicity, leading to decreased survival
in preclinical models [36–38]. Recent data demonstrated
that treatment with sunitinib in tumor-bearing mice for
5 days prior to chemotherapy resulted in a signiﬁcantly
greater improvement in animal survival when compared
with concurrent therapy and that VEGF antagonists
administered sequentially prior to chemotherapy protected
against chemotherapy-induced systemic toxicity to improve
survival [38]. As pemetrexed is not highly myelosuppres-
sive and has a good tolerability proﬁle [39], it is an ideal
chemotherapy to combine with an antiangiogenic agent.
However, despite the observed antitumor effects, toxicity
was increased with concurrent administration and continu-
ous dosing in our study. Although this single preclinical
study suggests that treatment with an antiangiogenic agent
prior to chemotherapy might be advantageous, it is unclear
whether these effects translate clinically and whether there
720 Cancer Chemother Pharmacol (2012) 69:709–722
123may be an optimal interval. Our study adds important
information regarding the combination of antiangiogenic
agents with chemotherapy in a setting where promising
antitumor activity and clinical beneﬁt were observed. In
light of recent advancements, consideration of future
exploration of sequencing and discontinuous regimens of
sunitinib in combination with pemetrexed may further
improve tolerability and optimize clinical responses.
In summary, it was possible to administer potentially
efﬁcacious doses of sunitinib on either a CDD schedule or
on Schedule 2/1 with full doses of pemetrexed in this phase
I study. Treatment was associated with an acceptable tox-
icity proﬁle, with a slow cumulative need for dose modi-
ﬁcations after multiple cycles. No clinically signiﬁcant
drug–drug interactions were observed. Sunitinib plus
pemetrexed on a CDD schedule at the MTD was selected
as the potential RP2D and was well tolerated. This dose/
regimen demonstrated substantial clinical activity among
NSCLC patients. In addition to determining the recom-
mended dosing regimen for further exploration compared
with pemetrexed monotherapy, these data also inform the
starting doses for possible further exploration in combi-
nation with a platinum agent, given the increasing use of
pemetrexed–platinum doublets in the ﬁrst-line treatment of
advanced NSCLC.
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